The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives

被引:39
作者
Pan, Fan [1 ]
Lin, Xin-Rong [1 ]
Hao, Li-Ping [1 ]
Chu, Xiao-Yuan [1 ]
Wan, Hai-Jun [2 ]
Wang, Rui [1 ]
机构
[1] Nanjing Univ, Med Sch, Affiliated Jinling Hosp, Dept Med Oncol, Nanjing, Peoples R China
[2] Nanjing Univ, Med Sch, Affiliated Jinling Hosp, Dept Gastroenterol, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
RNA modification; METTL3; m6A; Hepatocellular carcinoma; drug-resistance; HYPOXIA-INDUCIBLE FACTOR; MESSENGER-RNA; CANCER-CELL; TUMOR PROGRESSION; ONCOGENIC ROLE; NUCLEAR-RNA; PROMOTES; METHYLATION; METASTASIS; TRANSLATION;
D O I
10.3389/fcell.2021.674919
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Hepatocellular carcinoma (HCC) is the 6th most prevalent cancer and the 4th leading cause of cancer-related death worldwide. Mechanisms explaining the carcinogenesis of HCC are not clear yet. In recent years, rapid development of N-6-methyladenosine (m6A) modification provides a fresh approach to disclosing this mystery. As the most prevalent mRNA modification in eukaryotes, m6A modification is capable to post-transcriptionally affect RNA splicing, stability, and translation, thus participating in a variety of biological and pathological processes including cell proliferation, apoptosis, tumor invasion and metastasis. METTL3 has been recognized as a pivotal methyltransferase and essential to the performance of m6A modification. METTL3 can regulate RNA expression in a m6A-dependent manner and contribute to the carcinogenesis, tumor progression, and drug resistance of HCC. In the present review, we are going to make a clear summary of the known roles of METTL3 in HCC, and explicitly narrate the potential mechanisms for these roles.
引用
收藏
页数:9
相关论文
共 99 条
[1]   PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives [J].
Asati, Vivek ;
Mahapatra, Debarshi Kar ;
Bharti, Sanjay Kumar .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 109 :314-341
[2]   Evolutionary conservation of the DRACH signatures of potential N6-methyladenosine (m6A) sites among influenza A viruses [J].
Bayoumi, Mahmoud ;
Munir, Muhammad .
SCIENTIFIC REPORTS, 2021, 11 (01)
[3]  
Bokar JA, 1997, RNA, V3, P1233
[4]  
Bokar JA, 2005, TOP CURR GENET, V12, P141, DOI 10.1007/b106365
[5]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[6]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[7]   Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib [J].
Brunetti, Oronzo ;
Gnoni, Antonio ;
Licchetta, Antonella ;
Longo, Vito ;
Calabrese, Angela ;
Argentiero, Antonella ;
Delcuratolo, Sabina ;
Solimando, Antonio Giovanni ;
Casadei-Gardini, Andrea ;
Silvestris, Nicola .
MEDICINA-LITHUANIA, 2019, 55 (10)
[8]   RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 [J].
Burnett, PE ;
Barrow, RK ;
Cohen, NA ;
Snyder, SH ;
Sabatini, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (04) :1432-1437
[9]   EMT, cell plasticity and metastasis [J].
Chaffer, Christine L. ;
San Juan, Beatriz P. ;
Lim, Elgene ;
Weinberg, Robert A. .
CANCER AND METASTASIS REVIEWS, 2016, 35 (04) :645-654
[10]   RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2 [J].
Chen, Mengnuo ;
Wei, Lai ;
Law, Cheuk-Ting ;
Tsang, Felice Ho-Ching ;
Shen, Jialing ;
Cheng, Carol Lai-Hung ;
Tsang, Long-Hin ;
Ho, Daniel Wai-Hung ;
Chiu, David Kung-Chun ;
Lee, Joyce Man-Fong ;
Wong, Carmen Chak-Lui ;
Ng, Irene Oi-Lin ;
Wong, Chun-Ming .
HEPATOLOGY, 2018, 67 (06) :2254-2270